L Pusztai

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 26:4679-83. 2008
  2. ncbi Current status of prognostic profiling in breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Oncologist 13:350-60. 2008
  3. ncbi A clinically relevant gene signature in triple negative and basal-like breast cancer
    Achim Rody
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, Frankfurt, 60590, Germany
    Breast Cancer Res 13:R97. 2011
  4. ncbi Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile
    Chen Zhao
    The Center for Bioinformatics and The institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, 200241, China
    BMC Genomics 12:S3. 2011
  5. ncbi Maximizing biomarker discovery by minimizing gene signatures
    Chang Chang
    The Center for Bioinformatics and Institute of Biomedical Sciences, School of Life Science, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China
    BMC Genomics 12:S6. 2011
  6. ncbi Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer
    Catherine M Kelly
    Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland
    Oncologist 17:492-8. 2012
  7. ncbi Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
    Takayuki Iwamoto
    The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 30:729-34. 2012
  8. ncbi Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
    Takayuki Iwamoto
    Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77230 1439, USA
    Genome Med 2:81. 2010
  9. ncbi Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
  10. ncbi CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007

Research Grants

  1. Preoperative chemotherapy for breast cancer
    Lajos Pusztai; Fiscal Year: 2007

Collaborators

Detail Information

Publications123 found, 100 shown here

  1. ncbi Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 26:4679-83. 2008
    ....
  2. ncbi Current status of prognostic profiling in breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Oncologist 13:350-60. 2008
    ....
  3. ncbi A clinically relevant gene signature in triple negative and basal-like breast cancer
    Achim Rody
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, Frankfurt, 60590, Germany
    Breast Cancer Res 13:R97. 2011
    ..Triple negative breast cancers (TNBC) are clinically heterogeneous and prognostic markers and biology-based therapies are needed to better treat this disease...
  4. ncbi Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile
    Chen Zhao
    The Center for Bioinformatics and The institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, 200241, China
    BMC Genomics 12:S3. 2011
    ..Fine-tuning of model parameters and optimizing each step of the modeling process often results in over-fitting problems without improving performance...
  5. ncbi Maximizing biomarker discovery by minimizing gene signatures
    Chang Chang
    The Center for Bioinformatics and Institute of Biomedical Sciences, School of Life Science, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China
    BMC Genomics 12:S6. 2011
    ....
  6. ncbi Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer
    Catherine M Kelly
    Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland
    Oncologist 17:492-8. 2012
    ..To compare risk assignment by PAM50 Breast Cancer Intrinsic Classifier™ and Oncotype DX_Recurrence Score (RS) in the same population...
  7. ncbi Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
    Takayuki Iwamoto
    The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 30:729-34. 2012
    ....
  8. ncbi Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
    Takayuki Iwamoto
    Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77230 1439, USA
    Genome Med 2:81. 2010
    ....
  9. ncbi Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
    ..abstract:..
  10. ncbi CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
    ..We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC)...
  11. ncbi T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
    Achim Rody
    Department of Obstetrics and Gynecology, JW Goethe University, Theodor Stern Kai 7, Frankfurt, Germany
    Breast Cancer Res 11:R15. 2009
    ..However, specific lymphocytes might also promote tumor progression by shifting the cytokine milieu in the tumor...
  12. ncbi Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
    Vlad Popovici
    Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Genopode Building, Quartier Sorge, Lausanne CH 1015, Switzerland
    Breast Cancer Res 12:R5. 2010
    ....
  13. ncbi PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 10:R27. 2008
    ..In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer...
  14. ncbi Evaluation of biological pathways involved in chemotherapy response in breast cancer
    Attila Tordai
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res 10:R37. 2008
    ..Our goal was to examine the association between biological pathways and response to chemotherapy in estrogen receptor-positive (ER+) and ER-negative (ER-) breast tumors separately...
  15. ncbi Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
    Qiyuan Li
    Center for Biological Sequence Analysis, Department of Systems Biolology, Technical University of Denmark, 2800 Lyngby, Denmark
    BMC Bioinformatics 12:310. 2011
    ..However, identification of clinically predictive or prognostic classifiers can be challenging when a large number of genes are measured in a small number of tumors...
  16. ncbi Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses
    Rene Natowicz
    AP HP, Hopital Tenon, Department of Gynecology, 4 rue de la Chine, F 75020 Paris, France
    BMC Bioinformatics 9:149. 2008
    ..Multigenic predictors were designed by selecting probe sets highly ranked in their predictions and tested using several validation sets...
  17. ncbi Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
    Nat Clin Pract Oncol 1:44-50. 2004
    ..Here we review recent advances in the application of gene expression profiling to chemotherapy response prediction...
  18. ncbi Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Invest 24:187-91. 2006
    ....
  19. ncbi Clinical trial design for microarray predictive marker discovery and assessment
    L Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Oncol 15:1731-7. 2004
    ..This manuscript reviews methodological and statistical issues relevant to clinical trial design to discover and validate multigene predictors of response to therapy...
  20. ncbi Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4287-92. 2009
    ..Expression levels were correlated with disease-free survival (DFS) and overall survival (OS). Interaction between this marker and paclitaxel efficacy was also examined...
  21. ncbi Molecular classification of breast cancer: limitations and potential
    Lajos Pusztai
    D Phil, University of Texas M D Anderson Cancer Center, Department of Breast Medical Oncology, Unit1354, PO Box 301439, Houston, Texas 77230 1439, USA
    Oncologist 11:868-77. 2006
    ..To provide context for this discussion, we also briefly examine the performance of estrogen receptor immunohistochemistry, which represents an essential part of the routine diagnostic workup for all breast cancer patients...
  22. ncbi Markers predicting clinical benefit in breast cancer from microtubule-targeting agents
    L Pusztai
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77230 1439, USA
    Ann Oncol 18:xii15-20. 2007
    ..Large scale pharmacogenomic analysis has identified molecular markers potentially capable of distinguishing patients with differential sensitivity to paclitaxel and ixabepilone. These markers require validation in clinical trials...
  23. ncbi Chips to bedside: incorporation of microarray data into clinical practice
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-1439, USA
    Clin Cancer Res 12:7209-14. 2006
  24. ncbi Oncogenomics 2005--Dissecting Cancer through Genome Research. 2-6 February 2005, San Diego, CA, USA
    Lajos Pusztai
    MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston, TX 77030-4009, USA
    IDrugs 8:215-8. 2005
  25. ncbi Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 424, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Drug Resist Updat 7:325-31. 2004
    ..Perhaps, the most important challenge is to prospectively design and conduct validation trials that demonstrate clinical utility by showing improved patient outcomes with the use of a proposed new test...
  26. ncbi Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Breast Cancer 12:73-85. 2005
    ..D. Anderson Cancer Center. This manuscript is based on a presentation that was given during the Presidential Symposium of the annual meeting of the Japanese Breast Cancer Society in 2004...
  27. ncbi Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 13:6080-6. 2007
    ..We examined if supervised analysis of gene expression data from phase II studies could identify HER-2 overexpression as a predictor of response to trastuzumab...
  28. ncbi Limitations of pharmacogenomic predictor discovery in Phase II clinical trials
    Lajos Pusztai
    University of Texas, MD Anderson Cancer Center, Department of Breast Medical Oncology, Unit 1354, PO Box 301439, Houston, TX 77230 1439, USA
    Pharmacogenomics 8:1443-8. 2007
    ....
  29. ncbi New generation of molecular prognostic and predictive tests for breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Semin Oncol 34:S10-6. 2007
    ....
  30. ncbi Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:682-91. 2005
    ....
  31. ncbi Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems
    Kenneth R Hess
    Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, USA
    BMC Bioinformatics 12:463. 2011
    ..Prediction models were trained to identify which cases had been perturbed. Performance was estimated using Monte-Carlo cross validation...
  32. ncbi Clinical application of cDNA microarrays in oncology
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 8:252-8. 2003
    ..This paper reviews the current methodology and applications of this technique as they relate to clinical oncology...
  33. ncbi Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis
    Lajos Pusztai
    Department of Breast Medical Oncology, M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Oncologist 15:1164-8. 2010
    ..For patients with clinical courses consistent with hormone responsiveness, or with prior positive hormone receptor results, a course of endocrine therapy is reasonable regardless of the most recent hormone receptor assay result...
  34. ncbi Development of pharmacogenomic predictors for preoperative chemotherapy of breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 424, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA
    Adv Exp Med Biol 587:233-49. 2006
  35. ncbi Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Genet Cytogenet 141:148-53. 2003
    ..Taken together, these data suggest that expression profiling can be used diagnostically to distinguish individual histologic subclassifications and may guide the selection of target therapeutics...
  36. ncbi Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer
    Lajos Pusztai
    Box 424, Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 21:3454-61. 2003
    ..We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC)...
  37. ncbi The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches
    Lara Lacerda
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Drug Resist Updat 13:99-108. 2010
    ..This paper reviews current attempts to targeting TICs and discusses the competing hypotheses to explain breast cancer recurrence and therapy resistance...
  38. ncbi Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cytokine 25:94-102. 2004
    ..The objective of this study was to assess changes in plasma levels of interleukin (IL)-1beta, IL-6, IL-8, IL-10, IL-12, and TNF-alpha during chemotherapy and to correlate these changes with musculoskeletal symptoms...
  39. ncbi Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1814-22. 2004
    ..The authors also compared the plasma profiles of patients with cancer with the plasma profiles of healthy women to identify breast carcinoma-associated protein markers...
  40. ncbi Preoperative systemic chemotherapy and pathologic assessment of response
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, P O Box 301439, Houston, TX 77230 1439, USA
    Pathol Oncol Res 14:169-71. 2008
    ..Each component contributes meaningful pathologic information and can be obtained using routine pathologic materials and methods of interpretation that could easily be implemented in routine diagnostic practice...
  41. ncbi Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors
    Lajos Pusztai
    Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 009, USA
    Clin Cancer Res 9:2406-15. 2003
    ..33)P]dCTP-labeled cDNA probes were generated and hybridized to cDNA membrane microarrays that contained 30,000 human sequence clones, including 10,890 expressed sequence tags...
  42. ncbi Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
    F Peintinger
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Oncol 19:2020-5. 2008
    ....
  43. ncbi Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma
    H M Kuerer
    Department of Surgical Oncology, Box 444, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Surg 182:601-8. 2001
    ..Resection of the tumor bed remains necessary in women deemed to have a complete clinical response to ensure low rates of recurrence...
  44. ncbi Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
    F Andre
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 19:315-20. 2008
    ..We evaluated the expression patterns and predictive value of phosphorylated AKT (pAKT) in breast cancer tissues...
  45. ncbi Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Clin Cancer Res 11:5678-85. 2005
    ..CONCLUSIONS: The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers...
  46. ncbi Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
    C Mazouni
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Ann Oncol 18:874-80. 2007
    ....
  47. ncbi Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo
    P Wagner
    Deparment of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77230-1439, USA
    Cell Cycle 4:1149-52. 2005
    ....
  48. ncbi Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy
    T A Buchholz
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
    Cancer J 7:413-20. 2001
    ..However, more active systemic and local therapies are needed for patients with estrogen receptor-negative disease and positive lymph nodes and for those with clinical evidence of progressive disease during neoadjuvant chemotherapy...
  49. ncbi Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, BO Box 301439, Houston, TX 77030 1439, USA
    Breast Cancer Res Treat 121:301-9. 2010
    ..Cell line-derived predictors of response to four commonly used chemotherapy drugs did not predict response accurately in patients...
  50. ncbi Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..72 in the validation set and outperformed other prediction tools (P = .02). CONCLUSION: Our nomograms predict pCR accurately and can serve as a basis to integrate future molecular markers into a clinical prediction model...
  51. ncbi Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers
    Giampaolo Bianchini
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 28:4316-23. 2010
    ....
  52. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..This test correctly identified all but one of the patients who achieved pCR (12 of 13 patients) and all but one of those who were predicted to have residual disease had residual cancer (27 of 28 patients)...
  53. ncbi Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
    Radhika Rajan
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Cancer 100:1365-73. 2004
    ....
  54. ncbi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  55. ncbi Genomic grade index is associated with response to chemotherapy in patients with breast cancer
    Cornelia Liedtke
    DPhil, Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:3185-91. 2009
    ....
  56. ncbi DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design
    Fabrice Andre
    Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, United States
    Biochim Biophys Acta 1766:197-204. 2006
    ..Next, we will compare advantages and limitations of cohort-based and case-control studies. The choice of end-point to discriminate between sensitive and resistant patients will also be examined...
  57. ncbi Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond
    F J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 56, Houston, TX 77030, USA
    Oncologist 6:133-46. 2001
    ..Other novel biologic therapies interfere with signal transduction pathways and angiogenesis. The challenge for the next decade will be to integrate these promising agents in the management of metastatic and primary breast cancer...
  58. ncbi Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers
    C Mazouni
    Laboratoire de transfert biologique et oncologique, Marseille University, Houston, TX, USA
    Br J Cancer 99:68-71. 2008
    ..In conclusion, patients with breast cancer have elevated levels of collagen IV compared to healthy women and collagen IV levels increase further during chemotherapy...
  59. ncbi Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
    C Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77039, USA
    Ann Oncol 20:1953-8. 2009
    ..We evaluated discordance in expression measurements for estrogen receptor (ER), progesterone receptor (PR), and HER2 between primary and recurrent tumors in patients with recurrent breast cancer and its effect on prognosis...
  60. ncbi Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:1821-8. 2010
    ..Because many of these variables are also associated with response to NCT, novel molecular predictors are needed to identify patients at risk for progression on standard NCT...
  61. ncbi Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Box 424, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Cancer Invest 22:248-56. 2004
    ..However, it does not appear to determine response to doxorubicin-based chemotherapy. In contrast, lack of Bcl-2 expression was associated with a higher probability of complete pathological response to doxorubicin-based chemotherapy...
  62. ncbi Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:8315-20. 2005
    ..Low tau expression may be used as a marker to select patients for paclitaxel therapy. Inhibition of tau function might be exploited as a therapeutic strategy to increase sensitivity to paclitaxel...
  63. ncbi Development of candidate genomic markers to select breast cancer patients for dasatinib therapy
    Stacy Moulder
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 9:1120-7. 2010
    ..We defined three conceptually different potential predictors of dasatinib response that were reproducible across cell lines and human data. These candidate markers are being tested in a clinical trial to determine their utility...
  64. ncbi Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy
    Chafika Mazouni
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 109:496-501. 2007
    ....
  65. ncbi Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1459-66. 2006
    ..These tools may be useful when counseling patients about treatment options, and a web-based interface is now available to help guide patients and physicians in these decisions...
  66. ncbi Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
    Y Delpech
    1 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Department of Gynecology and Obstetrics, Lariboisiere Hospital, AP HP, Paris, France
    Br J Cancer 108:285-91. 2013
    ..Pathological complete responses are rare in both groups, but do not significantly differ after adjusting for other variables...
  67. ncbi Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer
    Y Delpech
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res Treat 135:619-27. 2012
    ..001). Low Ki67 expression in the primary tumor is associated with higher clinical benefit and longer time to progression on first-line endocrine therapy and longer survival after metastatic recurrence...
  68. ncbi A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
    W F Symmans
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Endocr Relat Cancer 12:1059-69. 2005
    ..036). GABApi gene expression is increased in breast cancers of immature (undifferentiated) cell type and is significantly associated with shorter lifetime history of breastfeeding and with high-grade breast cancer in Hispanic women...
  69. ncbi Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer
    F Peintinger
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Br J Surg 95:433-7. 2008
    ....
  70. ncbi Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry
    F J Esteva
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095, USA
    Pathol Oncol Res 7:171-7. 2001
    ..Further research is needed to determine the prognostic and predictive roles of the various associations between HER receptors, their ligands and signal transduction molecules in patients with early-stage breast cancer...
  71. ncbi Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer
    Judy C Boughey
    Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 244:464-70. 2006
    ..05). CONCLUSIONS: Among patients treated with BCT for larger breast tumors, patients treated with preoperative chemotherapy have less extensive resection, with no change in rates of re-excision...
  72. ncbi Global gene expression changes during neoadjuvant chemotherapy for human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 8:461-8. 2002
    ..A remarkable diversity in transcriptional response was observed for individual cases. Further data are needed to determine whether gene profiling can predict response to chemotherapy...
  73. ncbi Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma
    Fan Zhang
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1758-65. 2003
    ..CONCLUSIONS: The authors found no significant correlation between HER-2 expression and clinical or pathologic response to neoadjuvant chemotherapy in patients with breast carcinoma...
  74. ncbi Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations
    M Cristofanilli
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 19:1713-9. 2008
    ..We tested the activity of imatinib mesylate in MBC with overexpression of PDGFR or c-kit. Additionally, we sought to determine the biological correlates and immunomodulatory effects...
  75. ncbi Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits
    C H Yang
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 17:813-7. 2006
    ..The future development of this agent for the treatment of breast cancer should be guided by in vivo models that optimize activity in combination with other antitumor agents...
  76. ncbi Gene expression profiling of primary breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Unit 424, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 7:38-44. 2005
    ..The first multigene predictor of prognosis after tamoxifen therapy is already commercially available in the United States. This article reviews recent advances in the clinical application of this technique to breast cancer...
  77. ncbi A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes
    B Dutta
    Department of Systems Biology Unit 950, The University of Texas MD Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, USA
    Br J Cancer 106:1107-16. 2012
    ..For example, diverse transcriptomic and gene copy number variation data are currently collected for various cancers, but relatively few current methods are capable to utilise the emerging information...
  78. ncbi Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Oncologist 15:476-83. 2010
    ..In the present study, we assessed the efficacy of docetaxel in patients with metastatic breast cancer according to ER expression...
  79. ncbi RefSeq refinements of UniGene-based gene matching improve the correlation of expression measurements between two microarray platforms
    Yuan Ji
    Department of Biostatistics and Applied Mathematics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Appl Bioinformatics 5:89-98. 2006
    ..It is a sensible approach for matching probes across platforms.We conclude that UniGene alone is insufficient to match genes across platforms. Refined matching based on RefSeq significantly improves the quality of matches...
  80. ncbi Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:2636-43. 2008
    ..The aim of the present study was to assess the efficacy of adjuvant docetaxel and anthracycline therapy according to ER expression in two randomized clinical trials...
  81. ncbi Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:258-63. 2004
    ..45 and P = 0.14, respectively). CONCLUSIONS: her-2 gene amplification was not found to be predictive of a pathologic response to preoperative taxanes in patients with early-stage breast carcinoma...
  82. ncbi Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
    Fabrice Andre
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230-1439, USA
    Nat Clin Pract Oncol 3:621-32. 2006
    ..This Review describes the current limitations and future promises of gene-expression-based molecular classification of breast cancer and how it might impact on selection of adjuvant therapy for individual patients...
  83. ncbi Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
    Chafika Mazouni
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:2650-5. 2007
    ..To determine whether residual ductal carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patients with histologically defined complete eradication of invasive cancer...
  84. ncbi Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis
    Xiaohong Leng
    Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA
    Cancer Res 69:8579-84. 2009
    ..Our results suggest that inhibition of LCN2 function by an inhibitory monoclonal antibody has potential for breast cancer therapy, particularly by interfering with metastasis in aggressive types of breast cancer...
  85. ncbi Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
    Yun Gong
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 8:203-11. 2007
    ..Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling...
  86. ncbi Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010
    ..We hypothesize that measurement of gene expression related to estrogen receptor α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity to adjuvant endocrine therapy...
  87. ncbi Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:499-506. 2004
    ....
  88. ncbi Estrogen receptors and distinct patterns of breast cancer relapse
    Kenneth R Hess
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4409, USA
    Breast Cancer Res Treat 78:105-18. 2003
    ..We conducted an analysis of prospectively collected data to compare the clinical behavior of ER-negative versus ER-positive tumors with respect to rates and sites of recurrence...
  89. ncbi Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:676-81. 2005
    ..To the authors' knowledge there are few data that correlate the expression of the epidermal growth factor receptor (EGFR) with the outcome of patients who have breast carcinoma and are treated with anthracycline chemotherapy...
  90. ncbi Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:33-41. 2003
    ..We investigated whether changes in tumor cell apoptosis and Bcl-2 expression immediately after chemotherapy correlated with response to breast cancer treatment...
  91. ncbi Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:1800-8. 2002
    ..To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels...
  92. ncbi Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy
    Fabrice Andre
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Pharm Res 23:1951-8. 2006
    ....
  93. ncbi The use of microarray technology in the management of breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    Clin Adv Hematol Oncol 5:193-4, 197. 2007
  94. ncbi Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate
    Christine Y Shiang
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, P O Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res Treat 123:747-55. 2010
    ..These findings suggest that FGFR-1 amplification or protein overexpression in breast cancers may be an indicator for brivanib treatment, where it may have direct anti-proliferative effects in addition to its' anti-angiogenic effects...
  95. ncbi The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, Breast Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8398-402. 2005
    ....
  96. ncbi Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:5652-9. 2003
    ....
  97. ncbi Gene-expression microarrays provide new prognostic and predictive tests for breast cancer
    Yun Gong
    University of Texas, Department of Pathology, Anderson Cancer Center, Unit 53, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Pharmacogenomics 8:1359-68. 2007
    ..This review focuses on the recent progression in feasibility and reliability of gene-expression microarrays in identifying new prognostic and predictive indicators of breast cancer...
  98. ncbi Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2960-71. 2003
    ..This study compared gene expression profiles derived from fine-needle aspiration biopsy (FNAB) and from core needle biopsy (CBX)...
  99. ncbi Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:228-33. 2007
    ..All data were updated through November 2005...
  100. ncbi Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030 4009, USA
    J Clin Oncol 21:3249-54. 2003
    ..We conducted a phase II clinical trial to determine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer...
  101. ncbi Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
    J Clin Oncol 23:3676-85. 2005
    ....

Research Grants2

  1. Preoperative chemotherapy for breast cancer
    Lajos Pusztai; Fiscal Year: 2007
    ..We expect that our work will lead to the development of microarray-based clinical tests to personalize chemotherapy selection for an individual with newly diagnosed breast cancer. ..